Ocular nonsteroidal inflammatory drugs. Where do we stand today?

Ocular nonsteroidal inflammatory drugs. Where do we stand today? Cutan Ocul Toxicol. 2020 Apr 26;:1-26 Authors: Kandarakis SA, Petrou P, Papakonstantinou E, Spiropoulos D, Rapanou A, Georgalas I Abstract Since their first introduction in Ophthalmology, NSAIDs (nonsteroidal anti-inflammatory drugs) use has been exponentially expanded, with numerous therapeutic applications. Despite their controversial history, they have proven their efficacy as anti-inflammatory agents in a variety of diseases. Nowadays, NSAIDs are part of surgical protocols of the most commonly performed ophthalmic operations, such as cataract or ocular surgery. They are universally implicated in the management of conjunctivitis, retinal and choroidal disease and miscellaneous inflammatory diseases. Moreover, although linked with serious adverse events and toxicities, their therapeutic magnitude in Ophthalmology should not be affected. This review systematically portrays the variety of ocular NSAIDs available up to date, along with their differences on their way of action, indications and potential side effects in various ophthalmologic conditions. PMID: 32338073 [PubMed - as supplied by publisher]
Source: Cutaneous and Ocular Toxicology - Category: Toxicology Authors: Tags: Cutan Ocul Toxicol Source Type: research